Individualized Perioperative Antifibrinolytic Therapy: The Next Goal in Cardiac Surgery?

Bolliger, Daniel; Erb, Joachim M.

doi:10.1053/j.jvca.2020.08.033

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 Future incorporation of viscoelastic testing, fibrinolytic patterns, and assessment for therapeutic concentrations may better guide an individualized perioperative antifibrinolytic therapy approach in cardiac surgery. [55][56][57] TXA IN OBSTETRICS PPH is a leading cause of maternal death and morbidity. 58 Less clear is the extent to which hyperfibrinolysis contributes toward the magnitude of blood loss in women with severe PPH.…”

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Update on Applications and Limitations of Perioperative Tranexamic Acid

Patel

Wyrobek

Butwick

et al. 2022

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on patient blood management, TXA has become an integral aspect of perioperative blood conservation strategies. While clinical applications of TXA in the perioperative period are expanding, routine use in select clinical scenarios should be supported by evidence for efficacy. Furthermore, questions regarding optimal dosing without increased risk of adverse events such as thrombosis or seizures should be answered. Therefore, ongoing investigations into TXA utilization in cardiac surgery, obstetrics, acute trauma, orthopedic surgery, neurosurgery, pediatric surgery, and other perioperative settings continue. The aim of this review is to provide an update on the current applications and limitations of TXA use in the perioperative period. (Anesth Analg 2022;135:460-73)

show abstract